Vor Biopharma
35 hedge funds and large institutions have $91.9M invested in Vor Biopharma in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 19 closing their positions.
1,506% more call options, than puts
Call options by funds: $9.81M | Put options by funds: $611K
113% more capital invested
Capital invested by funds: $43.2M → $91.9M (+$48.7M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0.12% less ownership
Funds ownership: 2.41% → 2.28% (-0.12%)
24% less funds holding
Funds holding: 46 → 35 (-11)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$673K |
| 2 |
HF
HRT Financial
New York
|
+$210K |
| 3 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
+$178K |
| 4 |
Jane Street
New York
|
+$146K |
| 5 |
VF
Virtu Financial
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.91M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$170K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$126K |
| 4 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$106K |
| 5 |
Renaissance Technologies
New York
|
-$103K |
VOR Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2025, worth a combined $91.9M — up 113% from $43.2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VOR and 8 opened new positions — a net loss of 11 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was UBS Group, adding an estimated $673K. The largest seller was Fidelity Investments, cutting an estimated $1.91M.
- 35 institutional investors held Vor Biopharma (VOR) as of Q2 2025, down from 46 in Q1 2025.
- Funds reported $91.9M of Vor Biopharma stock for Q2 2025, up 113% quarter-over-quarter.
- 8 funds opened new Vor Biopharma positions in Q2 2025 and 19 closed out, a net change of -11 holders.
- The largest Vor Biopharma buyer in Q2 2025 was UBS Group, an estimated $673K added.
- The largest Vor Biopharma seller in Q2 2025 was Fidelity Investments, an estimated $1.91M sold.
Based on aggregated 13F filings for Q2 2025.